Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
Kitsada Wudhikarn, Miguel‐Angel Perales
Bone Marrow Transplantation (2022) Vol. 57, Iss. 10, pp. 1477-1488
Open Access | Times Cited: 77
Current and Emerging Knowledge in COVID-19
Yeon Joo Jeong, Yu Mi Wi, Hyunjin Park, et al.
Radiology (2023) Vol. 306, Iss. 2
Open Access | Times Cited: 72
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim Linton, Umberto Vitolo, Wojciech Jurczak, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 8, pp. e593-e605
Closed Access | Times Cited: 25
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Jon Salmanton‐García, Francesco Marchesi, Andreas Glenthøj, et al.
HemaSphere (2022) Vol. 6, Iss. 11, pp. e789-e789
Open Access | Times Cited: 33
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
Blood (2022) Vol. 140, Iss. 25, pp. 2709-2721
Open Access | Times Cited: 29
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients
Susana Patricia Amaya Hernandez, Ditte Stampe Hersby, Kamilla Kjærgaard Munk, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 15
Organokines in COVID-19: A Systematic Review
Sandra Maria Barbalho, Giulia Minniti, Vitor Fernando Bordin Miola, et al.
Cells (2023) Vol. 12, Iss. 10, pp. 1349-1349
Open Access | Times Cited: 15
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2653-2662
Open Access | Times Cited: 6
A Machine Learning approach to identify groups of patients with hematological malignant disorders
Pablo Rodríguez-Belenguer, José Luís Piñana, Manuel Sánchez-Montañés, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 246, pp. 108011-108011
Open Access | Times Cited: 5
Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
Kohei Kamegai, Naoya Itoh, Masahiro Ishikane, et al.
Journal of Infection and Chemotherapy (2025), pp. 102631-102631
Open Access
Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings
Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, et al.
Molecular Imaging and Radionuclide Therapy (2025) Vol. 34, Iss. 1, pp. 31-37
Open Access
Effect of Comorbidities on the Mortality of Patients With COVID‐19: A Systematic Review of Reviews and Meta‐Analyses
Karla Larissa Trassi Ganaza‐Domingues, Áquila Carolina Fernandes Herculano Ramos‐Milaré, Daniele Stéfanie Sara Lopes Lera‐Nonose, et al.
Reviews in Medical Virology (2025) Vol. 35, Iss. 2
Open Access
Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID‐19: A retrospective study
Hongbin Yu, Tian Chen, Jiawei Li, et al.
British Journal of Haematology (2025)
Closed Access
The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy
Kaushik Das, Tanmoy Mukherjee, Prem Shankar
Biomolecules (2023) Vol. 13, Iss. 6, pp. 897-897
Open Access | Times Cited: 13
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
Andrés Chang, Jean L. Koff, Lilin Lai, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2459-2462
Open Access | Times Cited: 12
Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy
H Qian, Xingcheng Yang, Ting-Ting Zhang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 662-678
Open Access | Times Cited: 4
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 10
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID‐19 infection at an ambulatory cancer center
Eduardo Sanchez, Elizabeth M. Krantz, Leah M. Yoke, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 3
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top